Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports

06-05-2024 | Abdominal Aortic Aneurysm | Review

Roles and Mechanisms of miRNAs in Abdominal Aortic Aneurysm: Signaling Pathways and Clinical Insights

Authors: Haorui Zhang, Ke Zhang, Yuanrui Gu, Yanxia Tu, Chenxi Ouyang

Published in: Current Atherosclerosis Reports

Login to get access

Abstract

Purpose of Review

Abdominal aortic aneurysm refers to a serious medical condition that can cause the irreversible expansion of the abdominal aorta, which can lead to ruptures that are associated with up to 80% mortality. Currently, surgical and interventional procedures are the only treatment options available for treating abdominal aortic aneurysm patients. In this review, we focus on the upstream and downstream molecules of the microRNA-related signaling pathways and discuss the roles, mechanisms, and targets of microRNAs in abdominal aortic aneurysm modulation to provide novel insights for precise and targeted drug therapy for the vast number of abdominal aortic aneurysm patients.

Recent Findings

Recent studies have highlighted that microRNAs, which are emerging as novel regulators of gene expression, are involved in the biological activities of regulating abdominal aortic aneurysms. Accumulating studies suggested that microRNAs modulate abdominal aortic aneurysm development through various signaling pathways that are yet to be comprehensively summarized.

Summary

A total of six signaling pathways (NF-κB signaling pathway, PI3K/AKT signaling pathway, MAPK signaling pathway, TGF-β signaling pathway, Wnt signaling pathway, and P53/P21 signaling pathway), and a total of 19 miRNAs are intimately associated with the biological properties of abdominal aortic aneurysm through targeting various essential molecules. MicroRNAs modulate the formation, progression, and rupture of abdominal aortic aneurysm by regulating smooth muscle cell proliferation and phenotype change, vascular inflammation and endothelium function, and extracellular matrix remodeling. Because of the broad crosstalk among signaling pathways, a comprehensive analysis of miRNA-mediated signaling pathways is necessary to construct a well-rounded upstream and downstream regulatory network for future basic and clinical research of AAA therapy.
Literature
1.
Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1991;13:452–8.
2.
Li X, Zhao G, Zhang J, Duan Z, Xin S. Prevalence and trends of the abdominal aortic aneurysms epidemic in general population–a meta-analysis. PLoS ONE. 2013;8:e81260.PubMedPubMedCentralCrossRef
3.
Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57–63.PubMedCrossRef
4.
Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605–13.PubMedCrossRef
5.
6.
Ailawadi G, Eliason JL, Upchurch GR. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg. 2003;38:584–8.PubMedCrossRef
7.
Li Y, Maegdefessel L. Non-coding RNA Contribution to Thoracic and Abdominal Aortic Aneurysm Disease Development and Progression. Front Physiol. 2017;8:429.PubMedPubMedCentralCrossRef
8.
Yu M, Chen Q, Li Q, Teng Y, Xiao L, Yang G, et al. A Disintegrin and Metalloprotease 10 Expressions Modulate Potential Metastatic and Thrombus Formation in Pancreatic Carcinoma. Iran J Public Health. 2022;51:1778–89.PubMedPubMedCentral
9.
Renfeng Q, Shuxiao C, Peixian G, Kun L, Xuedong F, Hai Y, et al. ADAM10 attenuates the development of abdominal aortic aneurysms in a mouse model. Mol Med Rep. 2021;24:774.PubMedCrossRef
10.
Chen Z, Ouyang C, Zhang H, Gu Y, Deng Y, Du C, et al. Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy. Autophagy. 2022;18:2270–87.
11.
Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75:855–62.PubMedCrossRef
12.
de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H, et al. An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol. 2017;35:872–8.PubMedPubMedCentralCrossRef
13.
Adam M, Raaz U, Spin JM, Tsao PS. MicroRNAs in Abdominal Aortic Aneurysm. Curr Vasc Pharmacol. 2015;13:280–90.PubMedCrossRef
14.
Borek A, Drzymała F, Botor M, Auguściak-Duma AM, Sieroń AL. Roles of microRNAs in abdominal aortic aneurysm pathogenesis and the possibility of their use as biomarkers. Kardiochir Torakochirurgia Pol. 2019;16:124–7.PubMedPubMedCentral
15.
Yu Q, Li Q, Yang X, Liu Q, Deng J, Zhao Y, et al. Dexmedetomidine suppresses the development of abdominal aortic aneurysm by downregulating the mircoRNA-21/PDCD 4 axis. Int J Mol Med. 2021;47:90.PubMedPubMedCentralCrossRef
16.
Yang Y, Ma Z, Yang G, Wan J, Li G, Du L, et al. Alginate oligosaccharide indirectly affects toll-like receptor signaling via the inhibition of microRNA-29b in aneurysm patients after endovascular aortic repair. Drug Des Devel Ther. 2017;11:2565–79.PubMedPubMedCentralCrossRef
17.
Zhang J, Zhao W-S, Xu L, Wang X, Li X-L, Yang X-C. Endothelium-specific endothelin-1 expression promotes pro-inflammatory macrophage activation by regulating miR-33/NR4A axis. Exp Cell Res. 2021;399:112443.PubMedCrossRef
18.
Murphy EP, Crean D. Molecular interactions between NR4A orphan nuclear receptors and NF-κB Are required for appropriate inflammatory responses and immune cell homeostasis. Biomolecules. 2015;5:1302–18. 
19.
Yu J, Liu R, Huang J, Wang L, Wang W. Inhibition of Phosphatidylinositol 3-kinease suppresses formation and progression of experimental abdominal aortic aneurysms. Sci Rep. 2017;7:15208.PubMedPubMedCentralCrossRef
20.
Shen G, Sun Q, Yao Y, Li S, Liu G, Yuan C, et al. Role of ADAM9 and miR-126 in the development of abdominal aortic aneurysm. Atherosclerosis. 2020;297:47–54.PubMedCrossRef
21.
Shi X, Ma W, Li Y, Wang H, Pan S, Tian Y, et al. MiR-144-5p limits experimental abdominal aortic aneurysm formation by mitigating M1 macrophage-associated inflammation: Suppression of TLR2 and OLR1. J Mol Cell Cardiol. 2020;143:1–14.PubMedCrossRef
22.
Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90.PubMedPubMedCentral
23.
Ma X, Yao H, Yang Y, Jin L, Wang Y, Wu L, et al. miR-195 suppresses abdominal aortic aneurysm through the TNF-α/NF-κB and VEGF/PI3K/Akt pathway. Int J Mol Med. 2018;41:2350–8.PubMed
24.
• Wang S, Wang J, Cai D, Li X, Zhong L, He X, et al. Reactive oxygen species-induced long intergenic noncoding RNA p21 accelerates abdominal aortic aneurysm formation by promoting secretary smooth muscle cell phenotypes. J Mol Cell Cardiol. 2023;174:63–76. This study deminstrated that reactive oxygen species-induced lincRNA-p21 sponges miR-204-5p to accelerate synthetic and proinflammatory SMC phenotypes through the Mekk3/NF-κB signaling pathway in AAA formation.PubMedCrossRef
25.
Zhao F, Chen T, Jiang N. CDR1as/miR-7/CKAP4 axis contributes to the pathogenesis of abdominal aortic aneurysm by regulating the proliferation and apoptosis of primary vascular smooth muscle cells. Exp Ther Med. 2020;19:3760–6.PubMedPubMedCentral
26.
Tuffy KM, Planey SL. Cytoskeleton-associated protein 4: functions beyond the endoplasmic reticulum in physiology and disease. Int Sch Res Not. 2012;2012:e142313.
27.
Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, Raiesdana A, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4:122ra22.PubMedPubMedCentralCrossRef
28.
Yang P, Peairs JJ, Tano R, Jaffe GJ. Oxidant-mediated Akt activation in human RPE cells. Invest Ophthalmol Vis Sci. 2006;47:4598–606.PubMedCrossRef
29.
Byeon SH, Lee SC, Choi SH, Lee H-K, Lee JH, Chu YK, et al. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci. 2010;51:1190–7.PubMedCrossRef
30.
Zhao L, Huang J, Zhu Y, Han S, Qing K, Wang J, et al. miR-33-5p knockdown attenuates abdominal aortic aneurysm progression via promoting target adenosine triphosphate-binding cassette transporter A1 expression and activating the PI3K/Akt signaling pathway. Perfusion. 2020;35:57–65.PubMedCrossRef
31.
Wang Y, Zhai S, Xing J, He Y, Li T. LncRNA GAS5 promotes abdominal aortic aneurysm formation through regulating the miR-185-5p/ADCY7 axis. Anticancer Drugs. 2022;33:225–34.PubMedCrossRef
32.
Ma D, Zheng B, Liu H-L, Zhao Y-B, Liu X, Zhang X-H, et al. Klf5 down-regulation induces vascular senescence through eIF5a depletion and mitochondrial fission. PLoS Biol. 2020;18:e3000808.PubMedPubMedCentralCrossRef
33.
You W, Hong Y, He H, Huang X, Tao W, Liang X, et al. TGF-β mediates aortic smooth muscle cell senescence in Marfan syndrome. Aging (Albany NY). 2019;11:3574–84.PubMedCrossRef
34.
Cooper HA, Cicalese S, Preston KJ, Kawai T, Okuno K, Choi ET, et al. Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm. Cardiovasc Res. 2021;117:971–82.PubMedCrossRef
35.
Nakao T, Horie T, Baba O, Nishiga M, Nishino T, Izuhara M, et al. Genetic ablation of MicroRNA-33 attenuates inflammation and abdominal aortic aneurysm formation via several anti-inflammatory pathways. Arterioscler Thromb Vasc Biol. 2017;37:2161–70.PubMedCrossRef
36.
Maguire EM, Pearce SWA, Xiao R, Oo AY, Xiao Q. Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection. Pharmaceuticals (Basel). 2019;12:118.PubMedCrossRef
37.
Wang Q, Shu C, Su J, Li X. A crosstalk triggered by hypoxia and maintained by MCP-1/miR-98/IL-6/p38 regulatory loop between human aortic smooth muscle cells and macrophages leads to aortic smooth muscle cells apoptosis via Stat1 activation. Int J Clin Exp Pathol. 2015;8:2670–9.PubMedPubMedCentral
38.
Shi C, Shen C, Liu G, Yang S, Ye F, Meng J, et al. NEAT1 promotes the repair of abdominal aortic aneurysms of endothelial progenitor cells via regulating miR-204-5p/Ang-1. Am J Transl Res. 2021;13:2111–26.PubMedPubMedCentral
39.
Zhang D, Lu D, Xu R, Zhai S, Zhang K. Inhibition of XIST attenuates abdominal aortic aneurysm in mice by regulating apoptosis of vascular smooth muscle cells through miR-762/MAP2K4 axis. Microvasc Res. 2022;140:104299.PubMedCrossRef
40.
Zou L, Xia P-F, Chen L, Hou Y-Y. XIST knockdown suppresses vascular smooth muscle cell proliferation and induces apoptosis by regulating miR-1264/WNT5A/β-catenin signaling in aneurysm. Biosci Rep. 2021;41:BSR20201810.PubMedPubMedCentralCrossRef
41.
42.
Kang H, Davis-Dusenbery BN, Nguyen PH, Lal A, Lieberman J, Van Aelst L, et al. Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem. 2012;287:3976–86.PubMedCrossRef
43.
Bi S, Liu R, He L, Li J, Gu J. Bioinformatics analysis of common key genes and pathways of intracranial, abdominal, and thoracic aneurysms. BMC Cardiovasc Disord. 2021;21:14.PubMedPubMedCentralCrossRef
44.
van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–32.PubMedPubMedCentralCrossRef
45.
Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, et al. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS ONE. 2011;6:e24568.PubMedPubMedCentralCrossRef
46.
Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23:252–65.PubMedPubMedCentralCrossRef
47.
Biros E, Moran CS, Wang Y, Walker PJ, Cardinal J, Golledge J. microRNA profiling in patients with abdominal aortic aneurysms: the significance of miR-155. Clin Sci (Lond). 2014;126:795–803.PubMedCrossRef
48.
Kalani M, Hodjati H, Ghoddusi Johari H, Doroudchi M. Memory T cells of patients with abdominal aortic aneurysm differentially expressed micro RNAs 21, 92a, 146a, 155, 326 and 663 in response to Helicobacter pylori and Lactobacillus acidophilus. Mol Immunol. 2021;130:77–84.PubMedCrossRef
49.
50.
Nie H, Zhao W, Wang S, Zhou W. Based on bioinformatics analysis lncrna SNHG5 modulates the function of vascular smooth muscle cells through mir-205-5p/SMAD4 in abdominal aortic aneurysm. Immun Inflamm Dis. 2021;9:1306–20.PubMedPubMedCentralCrossRef
51.
Jin Y, Wang W, Chai S, Liu J, Yang T, Wang J. Wnt5a attenuates hypoxia-induced pulmonary arteriolar remodeling and right ventricular hypertrophy in mice. Exp Biol Med (Maywood). 2015;240:1742–51.PubMedCrossRef
52.
Zhu H, He J, Ye L, Lin F, Hou J, Zhong Y, et al. Mechanisms of angiogenesis in a Curculigoside A-treated rat model of cerebral ischemia and reperfusion injury. Toxicol Appl Pharmacol. 2015;288:313–21.PubMedCrossRef
53.
Cao X, Cai Z, Liu J, Zhao Y, Wang X, Li X, et al. miRNA-504 inhibits p53-dependent vascular smooth muscle cell apoptosis and may prevent aneurysm formation. Mol Med Rep. 2017;16:2570–8.PubMedPubMedCentralCrossRef
54.
55.
Roy S, Khanna S, Hussain S-RA, Biswas S, Azad A, Rink C, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 2009;82:21–9.
56.
Kin K, Miyagawa S, Fukushima S, Shirakawa Y, Torikai K, Shimamura K, et al. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc. 2012;1:e000745.PubMedPubMedCentralCrossRef
57.
Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579–88.PubMedCrossRef
58.
Dai M, Zhu X, Zeng S, Liu Q, Hu R, Huang L, et al. Dexmedetomidine protects cells from Angiotensin II-induced smooth muscle cell phenotype switch and endothelial cell dysfunction. Cell Cycle. 2023;22:450–63.PubMedCrossRef
59.
Kunisawa T, Fujimoto K, Kurosawa A, Nagashima M, Matsui K, Hayashi D, et al. The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU. Ther Clin Risk Manag. 2014;10:797–806.PubMedPubMedCentralCrossRef
60.
• Yu Q, Zeng S, Hu R, Li M, Liu Q, Wang Y, et al. Dexmedetomidine Alleviates Abdominal Aortic Aneurysm by Activating Autophagy Via AMPK/mTOR Pathway. Cardiovasc Drugs Ther. 2023. This article not only proved that various signaling pathways are intimately assocated with the biological functions of abdominal aortic aneurysm, but also suggested that pharmaceuticals such as Dexmedetomidine might be of great efficacy and safety in the treatment of abdominal aortic aneurysm. Therefore, miRNAs might be targeted in clinical practice.
61.
Plana E, Gálvez L, Medina P, Navarro S, Fornés-Ferrer V, Panadero J, et al. Identification of Novel microRNA Profiles Dysregulated in Plasma and Tissue of Abdominal Aortic Aneurysm Patients. Int J Mol Sci. 2020;21:4600.PubMedPubMedCentralCrossRef
62.
Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, et al. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther. 2022;30:3462–76.PubMedPubMedCentralCrossRef
63.
Han Z, Zhang T, He Y, Li G, Li G, Jin X. Inhibition of prostaglandin E2 protects abdominal aortic aneurysm from expansion through regulating miR-29b-mediated fibrotic ECM expression. Exp Ther Med. 2018;16:155–60.PubMedPubMedCentral
64.
Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, Chin JT, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 2012;122:497–506.PubMedPubMedCentralCrossRef
65.
Price NL, Singh AK, Rotllan N, Goedeke L, Wing A, Canfrán-Duque A, et al. Genetic Ablation of miR-33 Increases Food Intake, Enhances Adipose Tissue Expansion, and Promotes Obesity and Insulin Resistance. Cell Rep. 2018;22:2133–45.PubMedPubMedCentralCrossRef
66.
Shahouzehi B, Eghbalian M, Fallah H, Aminizadeh S, Masoumi-Ardakani Y. Serum microRNA-33 levels in pre-diabetic and diabetic patients. Mol Biol Rep. 2021;48:4121–8.PubMedCrossRef
67.
Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921–31.PubMedPubMedCentralCrossRef
68.
Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Can J Physiol Pharmacol. 2003;81:578–87.PubMedCrossRef
69.
Yang D, Haemmig S, Chen J, McCoy M, Cheng HS, Zhou H, et al. Endothelial cell-specific deletion of a microRNA accelerates atherosclerosis. Atherosclerosis. 2022;350:9–18.PubMedPubMedCentralCrossRef
70.
Akiyoshi K, Fujimori T, Fu X, Shah AP, Yamaguchi A, Steenbergen C, et al. Adenosine A2A Receptor Regulates microRNA-181b Expression in Aorta: Therapeutic Implications for Large-Artery Stiffness. J Am Heart Assoc. 2023;12:e028421.PubMedPubMedCentralCrossRef
71.
Yang H, Shan L, Gao Y, Li L, Xu G, Wang B, et al. MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure. Dis Markers. 2021;2021:4572282.PubMedPubMedCentralCrossRef
72.
Di Gregoli K, Mohamad Anuar NN, Bianco R, White SJ, Newby AC, George SJ, et al. MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin. Circ Res. 2017;120:49–65.PubMedPubMedCentralCrossRef
73.
Hou X, Yang S, Zheng Y. Licochalcone A attenuates abdominal aortic aneurysm induced by angiotensin II via regulating the miR-181b/SIRT1/HO-1 signaling. J Cell Physiol. 2019;234:7560–8.PubMedCrossRef
74.
Kumar S, Boon RA, Maegdefessel L, Dimmeler S, Jo H. Role of Noncoding RNAs in the Pathogenesis of Abdominal Aortic Aneurysm. Circ Res. 2019;124:619–30.PubMedPubMedCentralCrossRef
75.
Chen J, Zhang K, Yang Y, Wu J. MiR-204–5p regulates HUVEC cell inflammation and apoptosis by targeting P4HB. Cell Mol Biol (Noisy-le-grand). 2023;69:207–12.
76.
77.
Xiong J, Zhou L, Zhou Y. LncRNA BBOX1-AS1 Contributes to the Development of Nasopharyngeal Carcinoma via miR-204-5p/MUC4 Axis. Ann Clin Lab Sci. 2023;53:366–79.PubMed
78.
Guo W, Gao R, Zhang W, Ge W, Ren M, Li B, et al. IgE aggravates the senescence of smooth muscle cells in abdominal aortic aneurysm by upregulating LincRNA-p21. Aging Dis. 2019;10:699–710.
79.
Fu W, Liu Z, Zhang J, Shi Y, Zhao R, Zhao H. Effect of microRNA-144-5p on the proliferation, invasion and migration of human umbilical vein endothelial cells by targeting SMAD1. Exp Ther Med. 2020;19:165–71.PubMed
80.
Yang G, Qin H, Liu B, Zhao X, Yin H. Mesenchymal stem cells-derived exosomes modulate vascular endothelial injury via miR-144-5p/PTEN in intracranial aneurysm. Hum Cell. 2021;34:1346–59.PubMedCrossRef
81.
Apollonova V, Plevako D, Garanin A, Sidina E, Zabegina L, Knyazeva M, et al. Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7. Cancer Drug Resist. 2023;6:596–610.PubMedPubMedCentralCrossRef
82.
Elabd WK, Elbakry MMM, Hassany M, Baki AA, Seoudi DM, El Azeem EMA. Evaluation of miRNA-7, miRNA-10 and miRNA-21 as diagnostic non-invasive biomarkers of hepatocellular carcinoma. Clin Exp Hepatol. 2023;9:221–7.PubMedPubMedCentralCrossRef
83.
Chambers P, Ziminska M, Elkashif A, Wilson J, Redmond J, Tzagiollari A, et al. The osteogenic and angiogenic potential of microRNA-26a delivered via a non-viral delivery peptide for bone repair. J Control Release. 2023;362:489–501.PubMedCrossRef
84.
Yang J, Dong W, Zhang H, Zhao H, Zeng Z, Zhang F, et al. Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma. Front Cell Dev Biol. 2022;10:927251.PubMedPubMedCentralCrossRef
85.
Peng J, He X, Zhang L, Liu P. MicroRNA-26a protects vascular smooth muscle cells against H2O2-induced injury through activation of the PTEN/AKT/mTOR pathway. Int J Mol Med. 2018;42:1367–78.PubMedPubMedCentral
86.
Yamasaki T, Horie T, Koyama S, Nakao T, Baba O, Kimura M, et al. Inhibition of microRNA-33b specifically ameliorates abdominal aortic aneurysm formation via suppression of inflammatory pathways. Sci Rep. 2022;12:11984.PubMedPubMedCentralCrossRef
87.
He X, Wang S, Li M, Zhong L, Zheng H, Sun Y, et al. Long noncoding RNA GAS5 induces abdominal aortic aneurysm formation by promoting smooth muscle apoptosis. Theranostics. 2019;9:5558–76.PubMedPubMedCentralCrossRef
88.
Le T, He X, Huang J, Liu S, Bai Y, Wu K. Knockdown of long noncoding RNA GAS5 reduces vascular smooth muscle cell apoptosis by inactivating EZH2-mediated RIG-I signaling pathway in abdominal aortic aneurysm. J Transl Med. 2021;19:466.PubMedPubMedCentralCrossRef
89.
Jiang Q, Han Y, Gao H, Tian R, Li P, Wang C. Ursolic acid induced anti-proliferation effects in rat primary vascular smooth muscle cells is associated with inhibition of microRNA-21 and subsequent PTEN/PI3K. Eur J Pharmacol. 2016;781:69–75.PubMedCrossRef
90.
Jiahui C, Jiadai Z, Nan Z, Rui Z, Lipin H, Jian H, et al. miR-19b-3p/PKNOX1 Regulates Viral Myocarditis by Regulating Macrophage Polarization. Front Genet. 2022;13:902453.PubMedPubMedCentralCrossRef
91.
Liao B, Dong S, Xu Z, Gao F, Zhang S, Liang R. MiR-19b-3p regulated by BC002059/ABHD10 axis promotes cell apoptosis in myocardial infarction. Biol Direct. 2022;17:20.PubMedPubMedCentralCrossRef
92.
Su Y, Sun Y, Tang Y, Li H, Wang X, Pan X, et al. Circulating miR-19b-3p as a Novel Prognostic Biomarker for Acute Heart Failure. J Am Heart Assoc. 2021;10:e022304.PubMedPubMedCentralCrossRef
93.
Zhang Y, Huang X, Sun T, Shi L, Liu B, Hong Y, et al. MicroRNA-19b-3p dysfunction of mesenchymal stem cell-derived exosomes from patients with abdominal aortic aneurysm impairs therapeutic efficacy. J Nanobiotechnology. 2023;21:135.PubMedPubMedCentralCrossRef
94.
Shi X-Y, Wang H, Wang W, Gu Y-H. MiR-98-5p regulates proliferation and metastasis of MCF-7 breast cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci. 2020;24:10914.PubMed
95.
Tan P, Li M, Liu Z, Li T, Zhao L, Fu W. Glycolysis-Related LINC02432/Hsa-miR-98-5p/HK2 Axis Inhibits Ferroptosis and Predicts Immune Infiltration, Tumor Mutation Burden, and Drug Sensitivity in Pancreatic Adenocarcinoma. Front Pharmacol. 2022;13:937413.PubMedPubMedCentralCrossRef
96.
Liu S, Huang J, Zhang Y, Liu Y, Zuo S, Li R. MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis. Aging (Albany NY). 2019;11:10697–710.PubMedCrossRef
97.
Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol. 2011;226:1035–43.PubMedPubMedCentralCrossRef
98.
Li J, Cen B, Chen S, He Y. MicroRNA-29b inhibits TGF-β1-induced fibrosis via regulation of the TGF-β1/Smad pathway in primary human endometrial stromal cells. Mol Med Rep. 2016;13:4229–37.PubMedPubMedCentralCrossRef
99.
Zhao L, Ouyang Y, Bai Y, Gong J, Liao H. miR-155-5p inhibits the viability of vascular smooth muscle cell via targeting FOS and ZIC3 to promote aneurysm formation. Eur J Pharmacol. 2019;853:145–52.PubMedCrossRef
100.
Zhang Z, Liang K, Zou G, Chen X, Shi S, Wang G, et al. Inhibition of miR-155 attenuates abdominal aortic aneurysm in mice by regulating macrophage-mediated inflammation. Biosci Rep. 2018;38:BSR20171432.PubMedPubMedCentralCrossRef
101.
Zampetaki A, Attia R, Mayr U, Gomes RSM, Phinikaridou A, Yin X, et al. Role of miR-195 in aortic aneurysmal disease. Circ Res. 2014;115:857–66.PubMedCrossRef
102.
Xu Z, Lang D, Wang D, Hu S, Yang L. LncRNA FGD5-AS1 Promotes Abdominal Aortic Aneurysm Growth Through the Activation of MMP3 in Vascular Smooth Muscle Cells. Int Heart J. 2023;64:470–82.PubMedCrossRef
103.
Gohlke L, Alahdab A, Oberhofer A, Worf K, Holdenrieder S, Michaelis M, et al. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC. Int J Mol Sci. 2023;24:14742.PubMedPubMedCentralCrossRef
104.
Yu S-L, Jeong D-U, Noh E-J, Jeon HJ, Lee DC, Kang M, et al. Exosomal miR-205-5p improves endometrial receptivity by upregulating E-Cadherin expression through ZEB1 inhibition. Int J Mol Sci. 2023;24:15149.PubMedPubMedCentralCrossRef
105.
Huang W, Zeng Z, Xu Y, Mai Z. Investigating whether exosomal miR-205-5p derived from tongue squamous cell carcinoma cells stimulates the angiogenic activity of HUVECs by targeting AMOT. Cancer Biomark. 2023;38:215–24.PubMedCrossRef
106.
Kim CW, Kumar S, Son DJ, Jang I-H, Griendling KK, Jo H. Prevention of abdominal aortic aneurysm by anti-microRNA-712 or anti-microRNA-205 in angiotensin II-infused mice. Arterioscler Thromb Vasc Biol. 2014;34:1412–21.PubMedPubMedCentralCrossRef
107.
Medzikovic L, Aryan L, Ruffenach G, Li M, Savalli N, Sun W, et al. Myocardial fibrosis and calcification are attenuated by microRNA-129-5p targeting Asporin and Sox9 in cardiac fibroblasts. JCI Insight. 2023;8:e168655.PubMedPubMedCentralCrossRef
108.
Qian Q, Ma Q, Wang B, Qian Q, Zhao C, Feng F, et al. Downregulated miR-129-5p expression inhibits rat pulmonary fibrosis by upregulating STAT1 gene expression in macrophages. Int Immunopharmacol. 2022;109:108880.PubMedCrossRef
109.
110.
Lee Y-S, Liang Y-C, Wu P, Kulber DA, Tanabe K, Chuong C-M, et al. STAT3 signalling pathway is implicated in keloid pathogenesis by preliminary transcriptome and open chromatin analyses. Exp Dermatol. 2019;28:480–4.PubMedPubMedCentralCrossRef
111.
Zheng Z, Li X, You H, Zheng X, Ruan X. LncRNA SOCS2-AS1 inhibits progression and metastasis of colorectal cancer through stabilizing SOCS2 and sponging miR-1264. Aging (Albany NY). 2020;12:10517–26.PubMedCrossRef
112.
Huang R, Yang Z, Liu Q, Liu B, Ding X, Wang Z. CircRNA DDX21 acts as a prognostic factor and sponge of miR-1264/QKI axis to weaken the progression of triple-negative breast cancer. Clin Transl Med. 2022;12:e768.PubMedPubMedCentralCrossRef
113.
Hu Z, Linn N, Li Q, Zhang K, Liao J, Han Q, et al. MitomiR-504 alleviates the copper-induced mitochondria-mediated apoptosis by suppressing Bak1 expression in porcine jejunal epithelial cells. Sci Total Environ. 2023;858:160157.PubMedCrossRef
114.
Liu Z, Zhang W, Zhang B, Chen S, Ling C. MiR-504-3p Has Tumor-Suppressing Activity and Decreases IFITM1 Expression in Non-Small Cell Lung Cancer Cells. Genet Test Mol Biomarkers. 2022;26:351–9.PubMedCrossRef
115.
Wu X, Yan L, Liu Y, Shang L. LncRNA ROR1-AS1 accelerates osteosarcoma invasion and proliferation through modulating miR-504. Aging (Albany NY). 2020;13:219–27.PubMedCrossRef
116.
Iyer V, Rowbotham S, Biros E, Bingley J, Golledge J. A systematic review investigating the association of microRNAs with human abdominal aortic aneurysms. Atherosclerosis. 2017;261:78–89.PubMedCrossRef
117.
118.
Tang Y, Fan W, Zou B, Yan W, Hou Y, Kwabena Agyare O, et al. TGF-β signaling and microRNA cross-talk regulates abdominal aortic aneurysm progression. Clin Chim Acta. 2021;515:90–5.PubMedCrossRef
119.
Pahl MC, Derr K, Gäbel G, Hinterseher I, Elmore JR, Schworer CM, et al. MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med Genomics. 2012;5:25.PubMedPubMedCentralCrossRef
Metadata
Title
Roles and Mechanisms of miRNAs in Abdominal Aortic Aneurysm: Signaling Pathways and Clinical Insights
Authors
Haorui Zhang
Ke Zhang
Yuanrui Gu
Yanxia Tu
Chenxi Ouyang
Publication date
06-05-2024
Publisher
Springer US
Published in
Current Atherosclerosis Reports
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-024-01204-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits